Is Glaucoma Hereditary? Family Risk, Genes and When to Get Screened

Blog

Is Glaucoma Hereditary? Family Risk, Genes and When to Get Screened

August 9, 2026

Yes, glaucoma is often hereditary, though usually not through a single gene. In the population-based Rotterdam Study, brothers, sisters and children of people with open-angle glaucoma had an estimated 22% lifetime risk of developing it, against 2.3% for relatives of people without glaucoma, about nine times higher. Most adult glaucoma comes from many genes acting together with age and other factors, and many people who develop it have no known family history. This page covers who should be screened, how often, and when genetic testing is useful.

When should relatives have eye exams? · What a glaucoma evaluation includes

Key Takeaways

  • A parent, sibling or child with glaucoma raises risk, but family history is not a diagnosis and absence of known history does not make someone immune.
  • A brother or sister with glaucoma raises your risk the most. In one large US survey, an affected brother or sister was linked with glaucoma being about 3.7 times as likely, and an affected parent about 2.2 times.
  • Most common adult primary open-angle glaucoma is genetically complex. It usually does not follow a simple “one gene means disease” inheritance pattern.
  • Clinical genetic testing is most useful for congenital, childhood, juvenile, syndromic or unusually strong familial glaucoma—not as a stand-alone screening test for every adult.
  • First-degree relatives should share the glaucoma type and age at diagnosis with an eye-care professional and receive risk-based comprehensive examinations.
  • A pressure check or vision-chart screening alone can miss glaucoma. Assessment may require dilation, optic-nerve evaluation, gonioscopy, pachymetry, OCT and visual fields.
  • A pathogenic familial variant can enable targeted testing, but incomplete penetrance and variable expression mean a positive result does not predict an exact outcome.
  • Direct, clear family communication works better than vague warnings. Share what is known, what relatives should do and why early disease can be silent.
  • Netra Restoration Therapy (NRT) cannot prevent inherited glaucoma, change genes or replace screening and pressure treatment. It may support function only after established disease is medically stable.

For the condition as a whole, including the types, symptoms, who is at risk, how it is diagnosed, today’s treatments and the trials testing nerve protection, read our glaucoma guide.

“Does glaucoma run in families?” has both a simple answer and a complicated one. Yes, family history is an established risk factor. Yet glaucoma is a group of disorders with different ages of onset, mechanisms and genetic architectures. A baby with primary congenital glaucoma, a 28-year-old with MYOC-related juvenile open-angle glaucoma and a 72-year-old with common primary open-angle glaucoma do not present the same inheritance question.

For most families, the immediate action is not ordering a consumer DNA kit. It is identifying who was affected, what type they had, how early and severely it behaved, and ensuring that close relatives receive appropriate eye examinations before symptoms appear. This article explains how to turn family history into proportionate prevention without genetic fatalism.

How much does a family history raise your risk?

Among close relatives, an affected brother or sister counts the most. In the Rotterdam Study in the Netherlands, eye doctors examined the close relatives of people with open-angle glaucoma and of people without it. Glaucoma was found in 10.4% of the patients’ brothers and sisters, compared with 0.7% of the brothers and sisters in the comparison group. The Baltimore Eye Survey in the United States, which examined 5,308 Black and white adults aged 40 and over, found the same pattern.

Relative reported to have glaucomaHow much more likely glaucoma was (Baltimore Eye Survey)
Brother or sisterAbout 3.7 times
ParentAbout 2.2 times
ChildAbout 1.1 times, so no clear link was found. This may be because many participants’ children were still too young to have glaucoma. If your child has glaucoma, tell your eye doctor, especially if it started young.
Grandparent, aunt, uncle or cousinNot measured. The risk is less clear, but still worth mentioning to your eye doctor.

These figures are odds ratios, adjusted for age, and they were slightly higher in Black than in white participants. Family history was based on what participants reported at an interview. The figures are averages and do not predict what will happen in one family. The family link also looked stronger in people who already knew they had glaucoma than in people first diagnosed at the survey: about 4.7 times compared with 2.8 times for an affected brother or sister. The researchers concluded that studies of clinic patients are likely to overstate the effect of family history.

Which types of glaucoma run in families?

All the main types can run in families, but in different ways. A few come mainly from a single gene with a clear pattern of inheritance. Most come from many genes, each adding a little risk. The sections further down explain each type in more detail.

Type of glaucomaHow it runs in families
Primary open-angle glaucoma (the most common adult type)Many genes, each adding a small amount of risk, together with age and eye pressure. Close relatives have a higher risk, but there is no single pattern of inheritance.
Juvenile open-angle glaucoma (diagnosed from about age 4 up to age 30 to 40)Sometimes a single gene. The most common is MYOC, passed down in a dominant pattern: each child of a parent with the variant has a 50% chance of inheriting it, though not everyone who inherits it develops glaucoma. A recessive gene, CYP1B1, is another cause.
Normal-tension glaucomaUsually many genes. Rarely, a single gene such as OPTN or TBK1 runs through several generations.
Primary congenital glaucoma (babies and young children)When a gene is found, it is usually a recessive one, most often CYP1B1. Each parent carries one changed copy without having the disease. When both parents are carriers, each child has a 1 in 4 chance of inheriting two changed copies.
Angle-closure (narrow-angle) glaucomaEye shape is partly inherited. In a study of Chinese patients with angle closure in Singapore, their brothers and sisters had an estimated 1 in 2 chance of narrow drainage angles, more than 7 times the rate in the general population.
Pseudoexfoliation glaucomaStrongly linked to common variants of the LOXL1 gene. These variants are also common in people who never develop it, so testing for them cannot reliably predict who will.
Pigmentary glaucomaOften runs in families, sometimes in a dominant pattern, and is more common in nearsighted people. Pigment rubs off the back of the iris and blocks the drainage tissue.
Glaucoma with developmental eye conditionsOften a single gene with dominant inheritance: FOXC1 or PITX2 in about half or more of people with Axenfeld–Rieger syndrome, and PAX6 in more than 9 in 10 people with aniridia.

What “hereditary” means—and what it does not

Genes influence how the eye’s drainage structures develop, how pressure is regulated, how connective tissue and the optic nerve respond to stress, and many other pathways. Some rare glaucomas are caused largely by a pathogenic variant in one gene. Common adult glaucoma more often reflects many genetic variants of small effect interacting with age, IOP, anatomy, ancestry, steroids and other factors.

Therefore, inheriting susceptibility is not the same as inheriting inevitable blindness. A relative may never develop disease, may develop it later, or may have a different course. Conversely, a person can develop glaucoma without any known affected relative because families are small, records are incomplete, disease was undiagnosed, or risk arose through a different combination.

Family history is clinically useful because it changes the prior probability. It tells the examiner to look carefully and helps determine surveillance. It cannot replace measurements of the actual eye.

Why family history is often incomplete

Open-angle glaucoma is usually painless and initially preserves central acuity. Older relatives may have called it “pressure,” “weak nerves” or simply “blindness.” They may remember using drops but not the diagnosis. Cataract, diabetic retinopathy, macular degeneration and stroke can be confused with glaucoma in family stories.

Adoption, estrangement, migration and early death limit knowledge. A family can also appear unaffected when relatives have not had comprehensive examinations. “No family history” often means “no family history that we know,” not proof of no genetic susceptibility.

Ask specific questions:

  • Who used lifelong pressure drops or had glaucoma laser or drainage surgery?
  • Was anyone diagnosed as a child or before age 40?
  • Did anyone lose side vision, stop driving or become blind from an eye disease?
  • Was the problem open-angle, angle-closure, congenital, pigmentary or pseudoexfoliative?
  • Did a relative have a very high pressure, low-pressure glaucoma or narrow angles?
  • Were both eyes affected, and at what age?
  • Has anyone had clinical genetic testing with a documented result?

Obtain records when possible. A pathology-free consumer family tree is not a substitute for them.

Which relatives are most relevant?

First-degree relatives—parents, full siblings and children—share the largest portion of genetic material and are the usual priority for communication. Half-siblings, grandparents, aunts, uncles and cousins also matter, particularly when several branches are affected or onset was early.

Risk is not uniform within a family. Siblings share genes and often early environment; age, ancestry, ocular anatomy and exposures still differ. The unaffected 30-year-old child of someone diagnosed at 78 has a different immediate context from the sibling of someone who needed surgery at 32.

A 2026 scoping review of family-screening programs found a median glaucoma prevalence of 11.25% and a median glaucoma-suspect prevalence of 19.45% among relatives across included studies. Estimates varied widely by relationship, population, diagnosis and program. These figures justify attention, not a prediction for one family.

Common adult open-angle glaucoma is usually polygenic

Genome-wide association studies have identified many loci associated with primary open-angle glaucoma, IOP, optic-disc features and corneal measurements. Each common variant generally changes risk only modestly. A polygenic risk score combines many variants into a relative-risk estimate.

Polygenic scores are promising for research and future screening strategies, but limitations matter. Performance can differ across ancestral populations because discovery datasets have not represented all groups equally. Thresholds, laboratories and clinical actions are not standardized. A high score does not diagnose optic neuropathy; a low score cannot rule it out.

Routine consumer genotyping also misses many rare variants, structural changes and clinically relevant regions. Results may be reclassified as science evolves. For typical later-onset primary open-angle glaucoma, examination remains more actionable than a commercial score.

Ancestry, race, and family risk require careful language

Population studies report differences in glaucoma prevalence, age of onset, blindness burden and angle-closure patterns across groups. In the United States, Black/African American adults have a higher burden of primary open-angle glaucoma, while angle-closure risk is higher in several Asian populations. Hispanic/Latino communities also carry substantial risk with aging. These findings inform outreach and examination timing; they do not make race a biological diagnosis.

Race is a social classification that imperfectly correlates with genetic ancestry. Disparities also reflect access to examinations, treatment affordability, environmental exposures, mistrust and unequal representation in research. Two people assigned the same racial category can have very different ancestry and ocular anatomy.

Clinicians should use population risk to reduce missed disease, not stereotype an individual or imply fault. Family history can add information within any ancestry, and anyone can develop glaucoma. Genetic databases that overrepresent European-ancestry participants may produce less accurate variant interpretation or polygenic scores for other populations—an important limitation when commercial tests claim precision.

The practical response is inclusive risk-based care: ask about self-identified background, migration and family diagnoses, examine the actual angle and optic nerve, and make follow-up accessible. A person should never be reassured solely because their demographic group is described as lower risk.

When a single gene may have greater clinical importance

Juvenile open-angle glaucoma and MYOC

Pathogenic variants in MYOC are a well-established cause of some juvenile and early adult open-angle glaucoma, often inherited in an autosomal-dominant pattern. That means each child of an affected variant carrier has a 50% chance of inheriting the variant, although penetrance, age and severity can vary by variant and family.

Early onset, very high pressure and multiple generations may prompt testing. If a pathogenic familial variant is found, targeted testing of relatives is more informative and less ambiguous than broad testing without a known family result.

Normal-tension glaucoma, OPTN, and TBK1

Rare pathogenic changes involving OPTN and copy-number changes involving TBK1 have been associated with familial normal-tension glaucoma. Most people with normal-tension glaucoma do not have one of these identifiable monogenic causes.

A strong autosomal-dominant pattern, unusually early onset or severe disease at pressures within the population range can support referral to an ocular geneticist or genetic counselor. Testing does not replace neurologic and ophthalmic assessment when the pattern is atypical.

Primary congenital glaucoma and CYP1B1

Primary congenital glaucoma can involve CYP1B1 and other genes. In many affected families, inheritance is autosomal recessive: parents carry one variant without having the childhood disease, while a child inherits two disease-causing copies. Frequencies and gene contributions vary by ancestry and consanguinity.

Cloudy enlarged corneas, tearing, light sensitivity or unusual eye size in an infant require urgent pediatric ophthalmology, not waiting for genetic results. Surgery is frequently central to treatment. Testing can clarify diagnosis, recurrence risk and surveillance of siblings when paired with counseling.

Developmental and syndromic glaucoma

Anterior-segment dysgenesis, aniridia and systemic syndromes can involve genes such as FOXC1, PITX2 or PAX6. The eye findings may occur with dental, umbilical, neurologic, renal or other features. Here, a molecular diagnosis can affect care beyond the eye and reproductive counseling.

The correct test depends on phenotype. Ordering a broad panel without a careful examination increases the chance of uncertain findings without answering the clinical question.

Angle-closure families and anatomy

Primary angle-closure disease also clusters in families and is influenced by heritable anatomy: shorter axial length, shallow anterior chamber, lens and iris configuration, among other features. It is genetically complex in most adults.

A relative of someone with angle closure should not assume that an open-angle genetic panel answers their risk. Gonioscopy or appropriate angle assessment is central. Anatomically narrow angles can exist without symptoms until intermittent or acute closure occurs.

Sudden severe eye pain, red eye, blurred vision or halos with headache, nausea or vomiting is an emergency. Family screening is preventive; it is not the response to an active attack.

Pseudoexfoliation, pigment dispersion, and secondary disease

Pseudoexfoliation syndrome has strong genetic associations, including variants near LOXL1, but common risk variants are frequent in people who never develop disease and vary across populations. Routine testing does not replace slit-lamp and dilated examination. Our guide to pseudoexfoliation glaucoma explains the condition.

Pigment dispersion and pigmentary glaucoma can cluster through inherited ocular anatomy. Myopia and characteristic iris configuration may contribute; our guide to pigmentary glaucoma explains how it develops. Again, gonioscopy and examination reveal what a DNA result alone cannot.

Traumatic and steroid-induced glaucomas are called secondary because an exposure or condition contributes, yet susceptibility can still run in families. Tell relatives about the diagnosis accurately; “ours was caused by an injury” may change—but not erase—their general need for eye care.

What an at-risk relative’s examination should include

A distance vision chart is not a glaucoma screen. Central acuity can remain excellent despite meaningful optic-nerve loss. Tonometry alone also misses people whose damaged nerve occurs at statistically normal IOP and flags many people with high pressure but no neuropathy.

A risk-based comprehensive evaluation can include:

  • personal, family, medication and steroid history;
  • visual acuity and refraction;
  • slit-lamp examination;
  • IOP measurement, sometimes at more than one visit;
  • pachymetry to contextualize corneal thickness;
  • gonioscopy to classify the drainage angle;
  • dilated optic-nerve and retinal examination;
  • optic-disc photography or OCT for a structural baseline; and
  • visual-field testing when indicated.

The first visit creates a baseline. Glaucoma is often diagnosed through a pattern or change over time rather than one borderline value. A normal examination today can still be valuable because it makes future change more detectable.

When should relatives begin, and how often should they return?

There is no single interval for every pedigree. The National Eye Institute advises people with a family history of glaucoma to receive a comprehensive dilated eye examination every one to two years, while recognizing that an eye-care professional may recommend more frequent assessment when risk is higher. Age, glaucoma type, age at onset in the affected relative, ancestry, pressure, corneal thickness, myopia, angle anatomy and baseline findings refine that schedule.

A child or young adult from a family with congenital or juvenile disease should not wait until the age used for routine adult screening. The treating specialist or genetics team can recommend examinations around the expected familial onset, sometimes beginning in infancy. Adult children of someone with typical late-onset glaucoma still benefit from establishing their own risk and baseline rather than waiting for symptoms.

A glaucoma suspect may need visits more frequently than an unaffected relative. The label “suspect” can reflect nerve appearance, high pressure, thin cornea, a field finding or angle anatomy; the reason should be documented. Surveillance ends neither after one normal pressure nor after a negative retail screening.

Screening, diagnosis, and surveillance are different

Screening sorts apparently well people into lower- and higher-concern groups. It does not make a definitive diagnosis. A community pressure check, fundus photo or AI result can improve access, but each has false positives and false negatives. Any abnormal screen needs a pathway to comprehensive evaluation.

Diagnosis integrates nerve structure, function, angle and risk. Surveillance asks whether a diagnosed or suspect eye is changing. The same OCT color code can have different meaning at these stages: an unusual baseline may be healthy anatomy, while credible serial thinning can be concerning even before a database label turns red.

Families should be told to request a “comprehensive glaucoma-risk evaluation,” not merely a glasses check or pressure test. Optometrists and ophthalmologists can identify risk and refer to a glaucoma specialist when findings are complex, progressive, advanced or surgical.

Who should consider clinical genetic counseling?

Referral is particularly reasonable when glaucoma is:

  • congenital, infantile, childhood or juvenile in onset;
  • present across several generations at unusually young ages;
  • associated with anterior-segment developmental abnormalities;
  • accompanied by systemic or syndromic features;
  • unusually severe for age or pressure;
  • consistent with a known monogenic family diagnosis; or
  • part of reproductive planning after a pathogenic variant is established.

A genetic counselor helps define the question, choose an appropriate accredited laboratory, explain possible results, document a pedigree and prepare for implications. An ocular geneticist can integrate phenotype with molecular findings. Testing the clearly affected family member first usually yields more information than testing an unaffected relative without knowing what to seek.

Understanding genetic-test results

Pathogenic or likely pathogenic

These classifications mean evidence supports a disease-causing role in the appropriate gene and phenotype. They do not necessarily predict age, pressure, severity or treatment response. The laboratory result must fit the person’s examination and inheritance pattern.

Variant of uncertain significance

A VUS is not a positive diagnosis and should not direct surgery or label healthy relatives as diseased. It means available evidence cannot determine whether the change is harmful. Family segregation and future research may lead to reclassification. Testing asymptomatic relatives solely for a VUS is usually not equivalent to predictive testing for a known pathogenic variant.

Negative result

A negative panel can mean no tested pathogenic variant was found. It does not prove that glaucoma is non-genetic: the causal gene may be unknown, the assay may not detect the change, or the condition may be polygenic. Clinical surveillance continues according to family history and eye findings.

Secondary or incidental findings

Broad exome or genome testing can identify unrelated health risks depending on consent and laboratory policy. Pretest discussion should cover whether these findings are sought, privacy, family implications and confirmatory testing. Raw-data interpretations from consumer services require clinical confirmation before medical action.

Penetrance, expression, and why relatives can differ

Penetrance describes the proportion of people with a variant who develop the associated phenotype. Variable expressivity describes differences in age, severity or manifestations among those affected. Both explain why a grandparent may have mild late disease while a child in the same family has earlier, higher-pressure glaucoma.

Environmental exposures and other genes can modify risk. So can access to screening and treatment: a person detected early may appear to have a milder course because pressure was controlled before major loss. Family comparisons therefore mix biology with health-care history.

These concepts prevent two errors. A healthy carrier should not be guaranteed that disease will occur, and an apparently unaffected older carrier should not be used to dismiss a pathogenic result in a younger relative. Counseling converts probability into an examination plan.

Building a useful glaucoma family record

Create a simple three-generation record with names or initials, biological relationships, eye diagnosis, age at diagnosis, procedures, severity and genetic report if available. Update it when someone receives a clarified diagnosis. Store the actual laboratory PDF, not only a screenshot that says “positive.”

Distinguish glaucoma from ocular hypertension, narrow angles and glaucoma suspect status. These conditions are related but not interchangeable. Record both eyes when the pattern differs. Note childhood eye surgery, absent iris, enlarged corneas or syndromic findings.

The record belongs to the family, not a social-media audience. Share the minimum necessary through secure channels and respect relatives who need time. Clinicians generally cannot contact relatives without permission, making patient-led communication important.

How to talk with relatives without causing panic

A useful message is concrete:

“I was diagnosed with primary open-angle glaucoma at age 52. It can be silent, and close relatives have higher risk. Please tell your eye-care professional and arrange a comprehensive dilated glaucoma evaluation rather than only a pressure check. Early detection allows treatment before noticeable loss.”

For a known variant, add the gene, exact laboratory classification and genetics contact. Do not translate “pathogenic variant” into “you will go blind.” If the type is unknown, say so and share the treating practice or records process.

Choose moments when relatives can act—family gatherings, milestone birthdays or annual reminders. Direct letters or calls may work better than handing one person leaflets to distribute. The 2026 family-screening review found substantially higher median response with direct contact than indirect messages through the affected patient, although program design and privacy rules varied.

Avoid blame. Genes are not caused by a parent’s choices, and delayed diagnosis often reflects silent disease and access barriers. The purpose is earlier care, not locating responsibility.

Reaching relatives across distance, language, and access barriers

Family members may live in different health systems or use different terms for eye care. Translate the diagnosis and request accurately. “Dilated comprehensive eye exam with glaucoma risk assessment” is more portable than a brand or local clinic name.

Teleophthalmology and community screening can improve reach, particularly when they include optic-nerve imaging and a reliable referral pathway. They do not make gonioscopy, confirmatory fields or longitudinal evaluation unnecessary. A screening event without affordable follow-up identifies a problem without solving it.

Insurance and transportation can be real barriers. In the United States, Medicare provides a glaucoma screening benefit for certain high-risk beneficiaries, including people with a family history, subject to its coverage rules and costs. Federally qualified health centers, academic programs and local blindness-prevention organizations may help locate care. Verify current eligibility rather than relying on an old brochure.

Children in an affected family

Most children of an adult with late-onset glaucoma do not need to be treated as if they have congenital disease. They still need ordinary pediatric vision care and a documented family history. Earlier specialist examination is warranted when the pedigree includes congenital, juvenile or developmental glaucoma, a known variant, high consanguinity or concerning signs.

Urgent pediatric signs include a cloudy or enlarging cornea, marked tearing, light sensitivity, eyelid squeezing, unusual eye asymmetry or apparent visual difficulty. Children may not report halos or field loss. A pediatric ophthalmologist can examine pressure, corneal diameter, refraction, nerve and angle, sometimes under anesthesia.

Genetic testing in a child should have a clear clinical or surveillance purpose and age-appropriate counseling. Predictive testing for an adult-onset susceptibility with no childhood action raises different ethical questions from testing a disorder that requires childhood monitoring.

Reproductive questions

When a pathogenic variant is established, a genetics professional can explain autosomal-dominant, autosomal-recessive, X-linked or more complex inheritance. Risk depends on the actual gene and variants, not the word glaucoma. Carrier testing, prenatal testing and preimplantation genetic testing may be technically possible in selected monogenic conditions, but these are personal decisions requiring specialized counseling.

The chance of inheriting a variant is not identical to the chance of severe visual disability because penetrance, expression, detection and treatment matter. Families deserve nondirective information rather than pressure toward one reproductive choice.

Privacy, discrimination, and consumer testing

Genetic information affects biological relatives as well as the person tested. Discuss who will receive results and how they will be stored. Laws and protections differ by country and may not cover life, disability or long-term-care insurance in the same way as health insurance. A genetics professional can explain current local considerations.

Direct-to-consumer reports may estimate susceptibility from a subset of variants, sometimes using data poorly calibrated for the user’s ancestry. They can create false reassurance or alarm. Any medically important finding requires confirmation in a clinical laboratory and interpretation against phenotype.

Do not upload relatives’ reports or identifiable pedigrees to public tools without consent. Convenience should not erase genomic privacy.

What families can do now

  1. Identify the glaucoma type and age at diagnosis in the affected person.
  2. Ask whether the ophthalmologist thinks the pattern warrants genetic counseling.
  3. Share a concise, non-alarming message with first-degree relatives.
  4. Arrange comprehensive examinations rather than pressure-only screening.
  5. Keep baseline results and follow the recommended interval.
  6. Store and share the exact clinical genetic report if one exists.
  7. Treat detected pressure or progression promptly; do not wait for symptoms.
  8. Update the family record when diagnoses change.

This sequence works whether or not molecular testing is useful. The most preventable family tragedy is not an undiscovered risk allele—it is a relative who knew glaucoma was in the family but waited for vision loss before being examined.

Where NRT fits—and where it cannot

NRT at Netra Eye Institute cannot change inherited risk, prevent glaucoma, lower IOP, replace a comprehensive examination or substitute for drops, laser or surgery. It does not make genetic testing more or less positive and cannot regenerate an injured optic nerve.

If a relative is newly diagnosed, the first priority is classification, target pressure and medical control. When established field loss remains after disease is stable, functional assessment may identify problems with visual search, contrast, reading, navigation or daily tasks. NRT may be one supportive component alongside low-vision optometry, accessibility technology and orientation-and-mobility training.

Functional improvement must not be described as reversal of inherited disease. Glaucoma stability remains determined through ophthalmic examination, IOP, OCT and perimetry.

Learn about Netra Restoration Therapy, Netra Eye Institute’s approach, glaucoma risk factors and glaucoma testing.

Frequently asked questions

Is glaucoma genetic?

Genes play a large part. A few rare forms follow a single-gene pattern, such as some juvenile open-angle glaucoma caused by variants in the MYOC gene. Common adult open-angle glaucoma involves many genes, each adding a small amount of risk, alongside age, eye pressure and other factors. “Genetic” means genes are involved; “hereditary” means the risk is passed down in families. Both apply to glaucoma, and neither means it is certain.

If my mother or father has glaucoma, will I get it?

Not necessarily, but your risk is higher, and it can come from either parent. Tell your eye doctor about glaucoma on either side of the family, which type it was and how old your relative was at diagnosis, since early onset points to a stronger inherited cause. In single-gene forms with dominant inheritance, such as MYOC-related glaucoma, each child of an affected parent has a 50% chance of inheriting the variant, though not everyone who inherits it develops glaucoma.

If my grandparent had glaucoma, am I at risk?

Possibly, a little. The clearest evidence of higher risk is for close relatives: brothers, sisters, parents and children, with the strongest link usually for an affected brother or sister. There is less research on grandparents, but a grandparent’s glaucoma is still worth mentioning at your eye exam, especially if it was diagnosed young or other relatives are affected.

Is glaucoma inherited from the mother or the father?

Either parent can pass it on. Most single-gene forms, such as MYOC glaucoma, are inherited the same way from a mother or a father. In the Barbados Eye Study, participants reported glaucoma in their mother about twice as often as in their father. That finding relied on what people remembered about their relatives, and on its own it does not show that glaucoma passes mainly through the mother. Tell your eye doctor about glaucoma on both sides of the family.

Why am I the first person in my family to have glaucoma?

You may not be. Early glaucoma usually causes no symptoms, and the National Eye Institute says half of people with glaucoma don’t know they have it, so relatives may have had it without a diagnosis. Older relatives may have died before the age when it usually appears, or described it in other words. Even in large Tasmanian families with many cases, more than 1 in 4 people already diagnosed did not know that other relatives had glaucoma, and examining the rest of the family found new cases. Common glaucoma also comes from many genes acting together, so a combination can come together in you for the first time. Your diagnosis now matters for your brothers, sisters and children, so ask them to get a full eye exam.

How do you prevent glaucoma if it runs in your family?

You cannot change the genes you inherit, but finding glaucoma early matters, because early treatment can often stop the damage and protect your sight. Get a full dilated eye exam every 1 to 2 years, as the National Eye Institute advises for people at higher risk, or as often as your eye doctor suggests. If your pressure is high or early damage is found, treatment lowers the risk of damage or of it getting worse. In the Ocular Hypertension Treatment Study, eye drops cut the share of people with high eye pressure who developed glaucoma within five years from 9.5% to 4.4%. In the Early Manifest Glaucoma Trial, treatment cut the share whose early glaucoma got worse over about six years from 62% to 45%.

At what age should I start eye exams if glaucoma runs in my family?

There is no single starting age. The National Eye Institute lists a family history of glaucoma as a reason for a comprehensive dilated eye exam every 1 to 2 years. Glaucoma UK, a patient charity, advises people with glaucoma to ask their close relatives to have an eye test at least every two years, and says this matters most for relatives over 40. Start earlier if your relative was diagnosed young, or if the family has childhood or juvenile glaucoma, when a specialist may advise checks from childhood. A first full exam also gives your eye doctor a baseline to compare later results against. Our guide to glaucoma tests explains what the exam includes.

What age does glaucoma usually start?

The common adult type is uncommon before 40 and becomes more common with age. In the Baltimore Eye Survey, about 1 in 100 people in their 40s had open-angle glaucoma. At 80 and over, it affected about 1 in 9 Black participants and about 1 in 50 white participants. Inherited single-gene forms can start much earlier: congenital glaucoma in the first few years of life, and juvenile open-angle glaucoma from about age 4 up to age 30 to 40.

What percentage of glaucoma is hereditary?

There is no single figure, because studies measure different things. Researchers estimate that genes account for about 70% of the differences between people in who develops primary open-angle glaucoma, which makes it one of the most heritable common diseases. This does not mean 70% of cases are inherited. In the Glaucoma Inheritance Study in Tasmania, which examined patients and their relatives, about 6 in 10 of the 1,700 people with open-angle glaucoma belonged to a family with other affected members. Because whole families were examined, this figure is higher than most studies find. In the general population of the Rotterdam Study, about 16% of glaucoma was linked to having an affected close relative. Many people with glaucoma have no known affected relative.

Is a normal pressure check enough?

No. Glaucoma can occur at statistically normal pressure, and high pressure can exist without nerve damage. Angle, nerve, field and other context matter.

Should everyone with glaucoma get a gene panel?

No. Yield and actionability are greatest in congenital, juvenile, syndromic or strongly familial patterns. Typical late-onset disease is often polygenic.

What does a negative genetic test mean for my children?

It means the test found no reportable pathogenic variant in what it assessed. Family-history risk and clinical screening may still apply.

Can a genetic result tell which drop will work?

Usually not in routine glaucoma care. Anatomy, pressure response, contraindications, side effects and progression guide treatment.

Can relatives wait until peripheral vision changes?

No. Early open-angle glaucoma is often silent, and lost field cannot currently be restored.

Does NRT reduce inherited glaucoma risk?

No. NRT is functional rehabilitation after medical stability; it is not genetic prevention or pressure treatment.

The bottom line

Family history is a call to examine, not a verdict. Most adult glaucoma reflects complex susceptibility, while a smaller group of early, developmental or strongly familial cases may benefit from clinical genetic testing and counseling. The precise diagnosis and age at onset determine which pathway makes sense over time.

Families protect sight by sharing accurate information, obtaining comprehensive baseline examinations and maintaining surveillance before symptoms. Genetics can sharpen that plan when results are actionable. It does not replace the plan.

A family message can remain simple and accurate: glaucoma may be silent, relatives share elevated risk, and screening requires more than a pressure reading. Providing the diagnosis type and age of onset is more useful than predicting that everyone will develop the same disease.

More on glaucoma

Related reading

References

  1. National Eye Institute. National Eye Institute Statement on Detection of Glaucoma and Adult Vision Screening. Updated October 27, 2025.
  2. National Eye Institute. Get a Dilated Eye Exam. Updated November 26, 2025.
  3. Kumar A, Han Y, Oatts JT. Genetic changes and testing associated with childhood glaucoma: a systematic review. PLOS ONE. 2024;19:e0298883.
  4. Family Screening in Glaucoma: A Scoping Review. Ophthalmology Glaucoma. 2026.
  5. Risk Factors and Genetic Markers Associated with the Development and Progression of Glaucoma: A Review. Journal of Current Glaucoma Practice. 2025;19:216–222.
  6. Diagnostic accuracy of next-generation sequencing-based genetic research for primary glaucoma: a systematic review and meta-analysis. 2025.
  7. Liu Y, Allingham RR. Molecular genetics of inherited normal-tension glaucoma. Journal of Glaucoma. 2024;33 Suppl 1:S335–S344.
  8. American Academy of Ophthalmology EyeWiki. The Genetics of Glaucoma. Updated 2026.
  9. Glaucoma Research Foundation. Genetic Testing in Glaucoma. Accessed August 2026.
  10. Glaucoma Research Foundation. Is Glaucoma Hereditary? Family History and Genetic Risks. Updated May 4, 2026.
  11. Wiggs JL, Pasquale LR. Genetics of glaucoma. Human Molecular Genetics. 2017;26:R21–R27.
  12. National Eye Institute. Medicare Benefit for Eye Health. Updated January 6, 2025.
  13. Wolfs RC, Klaver CC, Ramrattan RS, van Duijn CM, Hofman A, de Jong PT. Genetic risk of primary open-angle glaucoma: population-based familial aggregation study. Archives of Ophthalmology. 1998;116:1640–1645.
  14. Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey. Archives of Ophthalmology. 1994;112:69–73.
  15. Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266:369–374.
  16. Nemesure B, Leske MC, He Q, Mendell N. Analyses of reported family history of glaucoma: a preliminary investigation. The Barbados Eye Study Group. Ophthalmic Epidemiology. 1996;3:135–141.
  17. Green CM, Kearns LS, Wu J, et al. How significant is a family history of glaucoma? Experience from the Glaucoma Inheritance Study in Tasmania. Clinical and Experimental Ophthalmology. 2007;35:793–799.
  18. McNaught AI, Allen JG, Healey DL, et al. Accuracy and implications of a reported family history of glaucoma: experience from the Glaucoma Inheritance Study in Tasmania. Archives of Ophthalmology. 2000;118:900–904.
  19. Amerasinghe N, Zhang J, Thalamuthu A, et al. The heritability and sibling risk of angle closure in Asians. Ophthalmology. 2011;118:480–485.
  20. Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science. 2007;317:1397–1400.
  21. Kolovos A, Maxwell G, Souzeau E, Craig JE. Progress in translating glaucoma genetics into the clinic: a review. Clinical and Experimental Ophthalmology. 2025;53:246–259.
  22. Rong S, Yu X, Wiggs JL. Genetic basis of pigment dispersion syndrome and pigmentary glaucoma: an update and functional insights. Genes (Basel). 2024;15:142.
  23. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of Ophthalmology. 2002;120:701–713.
  24. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology. 2002;120:1268–1279.
  25. National Eye Institute. Glaucoma. Updated August 19, 2026.
  26. Glaucoma UK. Glaucoma and Your Relatives. Last reviewed May 2025.

Medical Disclaimer: This article provides general education and is not medical, genetic or reproductive advice. Family history and genetic results require interpretation by qualified eye-care and genetics professionals. Do not delay comprehensive examinations or prescribed pressure treatment while seeking testing. Sudden severe eye pain, redness, blurred vision, halos, nausea or vomiting requires emergency care. NRT does not prevent or treat glaucoma and must never delay medical care.

More From the Blog